Sun Pharma & Moebius Reveal Promising MM-II Osteoarthritis Data

25 Apr 2025 CW Team

Sun Pharmaceutical Industries Limited (Sun Pharma) and Israel-based Moebius Medical have jointly announced the publication of two peer-reviewed articles in Osteoarthritis and Cartilage, the official journal of the Osteoarthritis Research Society International (OARSI). These publications present key clinical and mechanistic findings on MM-II, an innovative, non-opioid treatment designed to relieve symptoms of knee osteoarthritis (OA).

MM-II is formulated as a proprietary suspension of large, empty, multilamellar liposomes. It aims to reduce joint friction and wear, ultimately alleviating pain and preserving joint health. The two new publications detail the product's significant pain relief results and unique cartilage-protective mechanism.

Key Publication Highlights:

Clinical Efficacy: The first study shares data from a Phase 2b randomised, double-blind, placebo-controlled clinical trial (NCT04506463), involving 397 participants across the US, Europe, and Asia. A single MM-II injection delivered sustained and meaningful pain relief for up to 26 weeks, with a favourable safety and tolerability profile. Read more

Mechanism of Action: The second article, titled “Empty large liposomes reduce cartilage degeneration in osteoarthritic rats by forming a lubricative coating,” reveals MM-II’s action at the cartilage level. It demonstrates that MM-II forms a lubricative layer over cartilage surfaces, reducing mechanical wear and slowing cartilage degeneration—mechanisms that may contribute to its long-term analgesic effects.

Technology

28 Oct 2025

Building Faster, Smarter, and Greener!

Backed by ULCCS’s century-old legacy, U-Sphere combines technology, modular design and sustainable practices to deliver faster and more efficient projects. In an interaction with CW, Rohit Prabhakar, Director - Business Development, shares how the company’s integrated model of ‘Speed-Build’, ‘Smart-Build’ and ‘Sustain-Build’ is redefining construction efficiency, quality and environmental responsibility in India.U-Sphere positions itself at the intersection of speed, sustainability and smart design. How does this translate into measurable efficiency on the ground?At U..

Smart Roads, Smarter India

India’s infrastructure boom is not only about laying more kilometres of highways – it’s about building them smarter, safer and more sustainably. From drones mapping fragile Himalayan slopes to 3D machine-controlled graders reducing human error, technology is steadily reshaping the way projects are planned and executed. Yet, the journey towards digitisation remains complex, demanding not just capital but also coordination, training and vision.Until recently, engineers largely depended on Survey of India toposheets and traditional survey methods like total stations or DGPS to prepare detai..

What Does DCPR 2034 Mean?

The Maharashtra government has eased approval norms for high-rise buildings under DCPR 2034, enabling the municipal commissioner to sanction projects up to 180 m on large plots. This change is expected to streamline approvals, reduce procedural delays and accelerate redevelopment, drawing reactions from developers, planners and industry experts about its implications for Mumbai’s vertical growth.Under the revised DCPR 2034 rules, buildings on plots of 2,000 sq m or more can now be approved up to 180 m by the municipal commissioner, provided structural and geotechnical reports are certified b..